|
|
|
(State or other jurisdiction of
incorporation) |
(Commission File Number)
|
(IRS Employer
Identification Number) |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Exhibit No.
|
Description
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
Vistagen Therapeutics, Inc.
|
|||
Date: July 7, 2023
|
By:
|
/s/ Shawn K. Singh
|
|
Shawn K. Singh
Chief Executive Officer
|
Document And Entity Information |
Jul. 07, 2023 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | Vistagen Therapeutics, Inc. |
Document, Type | 8-K |
Document, Period End Date | Jul. 07, 2023 |
Entity, Incorporation, State or Country Code | NV |
Entity, File Number | 000-54014 |
Entity, Tax Identification Number | 20-5093315 |
Entity, Address, Address Line One | 343 Allerton Ave. |
Entity, Address, City or Town | South San Francisco |
Entity, Address, State or Province | CA |
Entity, Address, Postal Zip Code | 94080 |
City Area Code | 650 |
Local Phone Number | 577-3600 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | VTGN |
Security Exchange Name | NASDAQ |
Entity, Emerging Growth Company | false |
Amendment Flag | false |
Entity, Central Index Key | 0001411685 |
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end